Clinical Trial Update: Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of BL-8040 plus atezolizumab as maintenance therapy in acute myeloid leukemia; the study was terminated and results were posted on 2024-09-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Atezolizumab (atezolizumab)
• BL-8040

Snippet

Sponsor: BioLineRx, Ltd. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-09-05